Since 1996 WHN is the second oldest medical website on the net, second only to the American Medical Association, servicing over 35,000 physicians and scientists worldwide.
Non-Profit Trusted Source of Non-Commercial Health Information
Tumors constantly shed DNA from dying cells, which briefly circulates in the patient’s bloodstream before it is quickly broken down. Many companies have created blood tests that can pick out this tumor DNA, potentially helping doctors diagnose or monitor cancer or choose a treatment. The amount of tumor DNA circulating at any given time, however, …
Individuals with obesity are more likely to have monoclonal gammopathy of undetermined significance (MGUS), a benign blood condition that often precedes multiple myeloma, according to new research published in Blood Advances. Multiple myeloma is a blood cancer of the plasma cells, a type of white blood cells that produce antibodies to fight infection. MGUS, characterized …
Research matters highlights: An experimental approach that combines cat allergy shots with a monoclonal antibody led to more effective relief that continued a year after treatment ended. This approach might also be effective for other types of allergies, including food allergies For people with cat allergies, exposure to these furry creatures can lead to a …
One injection of a candidate monoclonal antibody (mAb) known as L9LS was found to be safe and highly protective in U.S. adults exposed to the malaria parasite, according to results from a National Institutes of Health Phase 1 clinical trial published in The New England Journal of Medicine. Additional clinical trials evaluating if L9LS can …
In a groundbreaking study, scientists describe how the Ebola virus, which can persist in certain areas of the body, can re-emerge to cause fatal disease — even long after treatment with monoclonal antibodies. Their research, using a nonhuman primate model of Ebola virus infection, appears in Science Translational Medicine. Some recent Ebola virus disease outbreaks …
The FDA has revised the EUA to authorize bamlanivimab and etesevimab monoclonal antibody therapy when administered together for post-exposure prevention in certain individuals who are at high risk for severe infection or death; people should consult with their healthcare provider to find out if this post-exposure therapy is appropriate for them. A monoclonal antibody is …
A monoclonal antibody prevented malaria in people for up to 36 weeks in a Phase 1 clinical trial. Such antibodies could have a variety of uses for travelers, military personnel, health care workers, and campaigns to control and eliminate malaria. Malaria affects 200-400 million people worldwide each year. It kills nearly 400,000. Malaria incidence is …
A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the …
A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well-tolerated and generally safe when administered simultaneously to healthy adults. The experimental mAbs, REGN3048, and REGN3051, target the MERS coronavirus (MERS CoV) spike protein used by the virus …
In a phase 2 randomized clinical trial of adults with type 2 diabetes and obesity published in JAMA Network Open, investigational drug bimagrumab (BYM338, Novartis) — a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth — led to big reductions in total body fat mass and A1c and significant increases …